Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. grew its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 2.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 493,982 shares of the company’s stock after acquiring an additional 10,644 shares during the quarter. Federated Hermes Inc.’s holdings in Zentalis Pharmaceuticals were worth $1,497,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Prudential Financial Inc. purchased a new position in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $39,000. Ieq Capital LLC purchased a new position in shares of Zentalis Pharmaceuticals in the 4th quarter valued at $46,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Zentalis Pharmaceuticals during the 4th quarter valued at $53,000. Meriwether Wealth & Planning LLC purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter worth $66,000. Finally, Raymond James Financial Inc. acquired a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at $68,000.

Zentalis Pharmaceuticals Stock Performance

Shares of Zentalis Pharmaceuticals stock opened at $1.22 on Tuesday. The firm’s 50-day simple moving average is $1.82 and its 200-day simple moving average is $2.62. Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.01 and a 1 year high of $13.77. The firm has a market cap of $87.61 million, a PE ratio of -0.49 and a beta of 1.80.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.09. The firm had revenue of $26.90 million for the quarter. On average, equities analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on ZNTL shares. Wedbush restated a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, March 28th. Wells Fargo & Company reduced their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday, March 27th. Finally, UBS Group dropped their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $8.24.

Insider Transactions at Zentalis Pharmaceuticals

In related news, Director Jan Skvarka purchased 60,000 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the transaction, the director now owns 149,551 shares of the company’s stock, valued at $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Ingmar Bruns acquired 20,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Thursday, February 6th. The shares were bought at an average price of $2.28 per share, with a total value of $45,600.00. Following the transaction, the insider now directly owns 36,629 shares in the company, valued at approximately $83,514.12. This trade represents a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 3.60% of the company’s stock.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.